The In Vivo Lead will drive the design, execution, and interpretation of in vivo studies supporting radiopharmaceutical drug discovery and development programs at ARTBIO. This individual will provide both scientific and operational leadership, mentor team members, and ensure the generation of high-quality, timely data to inform key development decisions. The role requires close cross-functional collaboration with radiochemistry, biology, and discovery teams to define and advance the vision and capabilities for the vivo discipline at ARTBIO.

Responsibilities

Define and execute the strategic vision for the in vivo discipline, including recruiting, developing, and leading a high-performing team aligned with organizational goals

Foster strong partnerships within the broader Discovery organization, ensuring clear communication of priorities, timelines, and data delivery.

Identify technical or capacity gaps and proactively establish external collaborations to ensure delivery of critical, decision-enabling data.

Own the experimental rigor, data quality, and interpretation from the functional line by supporting technical development of the team and expansion of capabilities to increase efficiency (e.g., imaging, ICP-MS).

Continuously evolve in vivo capabilities to meet current and future portfolio needs.

Partner cross-functionally with the radiochemistry and discovery biology teams to support experimental design, understand the needs, and support in vivo studies.

Ensure strict adherence to Environment, Health & Safety (EHS) standards and Electronic Lab Notebook (ELN) compliance.

Establish and lead effective systems for resource planning and data sharing to support decision-making in a matrixed organization.

Qualifications & Education

PhD in pharmacology, biology, or related life science discipline with 7+ years of relevant postdoctoral and/or industry experience.

4+ years of leadership experience managing in vivo teams within oncology in a biotech, pharmaceutical, or CRO setting.

Demonstrated ability to think strategically and drive scientific innovation.

Experience with complex in vivo oncology models, including cell line–derived xenografts (CDX), patient-derived xenografts (PDX), and syngeneic models.

Experience in the identification, validation, and incorporation of translational biomarkers to elucidate mechanism of action.

Established track record as a scientific leader, including authorship of peer-reviewed publications and participation in oncology conferences.

Prior experience working with radiopharmaceuticals, including study design, execution, and interpretation of radioligand-based in vivo experiments.